Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Yuval Cohen |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts 02062 United States | |
| Phone | 617 963 0100 |
| Website | corbuspharma.com |
Stock Details
| Ticker Symbol | CRBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595097 |
| CUSIP Number | 21833P103 |
| ISIN Number | US21833P3010 |
| Employer ID | 46-4348039 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
| Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
| Christina Bertsch | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 144 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | 144 | Filing |
| Feb 14, 2025 | 144 | Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Dec 3, 2024 | 8-K | Current Report |